# US 2016/0354465 A1 · Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of Lingo-1 Antagonists and TrkB Agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354465 A1
- Document ID: US20160354465A1
- Status: Published application
- Kind: A1
- Application number: 15/155,399
- Filed: 2016-05-16
- Published: 2016-12-08
- Earliest claimed: 2007-10-11
- Assignees: Biogen MA Inc.
- Applicants: Biogen MA Inc.
- Inventors: Sha Mi
- Web page: https://patentgrep.com/patent/US20160354465A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method for promoting survival of retinal ganglion cells in a human subject displaying signs or symptoms of a pressure induced ocular neuropathy, the method comprising administering to the human subject a therapeutically effective amount of a combination of a LINGO-1 antagonist and a TrkB agonist.

### Claim at position 3

-10. (canceled)

### Claim 11 (depends on 8)

The method of claim 8, wherein said LINGO-1 antagonist comprises a soluble LINGO-1 polypeptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein said soluble LINGO-1 polypeptide comprises LINGO-1 region selected from the group consisting of:
(i) a LINGO Ig domain or a fragment, variant, or derivative thereof,
(ii) a LINGO LRR domain or a fragment, variant, or derivative thereof,
(iii) a LINGO cytoplasmic domain or a fragment, variant, or derivative thereof,
(iv) a LINGO transmembrane domain or a fragment, variant, or derivative thereof,
(v) a LINGO basic region C-terminal to the LRR domain or a fragment, variant, or derivative thereof, and
(vi) a combination of at least two of said LINGO-1 domains or a fragments, variants, or derivatives thereof of (i) to (v).

### Claim at position 6

-31. (canceled)

### Claim 32 (depends on 8)

The method of claim 8, wherein said LINGO-1 antagonist comprises a LINGO-1 antibody, or fragment thereof.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The method of claim 32, wherein said LINGO-1 antibody is selected from the group consisting of: 201′, 3A3, 3A6, 3B5, 1A7, 1D5, 1G7, 2B10, 2C11, 2F3, 3P1B1.1F9, 3P1D10.2C3, 3P1E11.3B7, 3P2C6.3G10.2H7, 3P2C9.2G4, 3P4A6.1D9, 3P4A1.2B9, 3P4C2.2D2, 3P4C5.1D8, 3P4C8.2G9, 6P4F4.1Ds, 6P4F4.1F9, 7P1D5.1G9, 1B6.4, 2C7.2, 2D6.1, 2F7.3, 2H3.2, 3C11.1, 3E3.1, 3H11.2, 3G8.1, 2B8.1, 3B5.230-C12 (Li01), 38-D01 (Li02), 35-E04 (Li03), 36-C09 (Li04), 30-A11 (Li05), 34-F02 (Li06), 29-E07 (Li07), 34-G04 (Li08), 36-A12 (Li09), 28-D02 (Li10), 30-B01 (Li11), 34-B03 (Li12), Li13, Li32, Li33, Li34, 3383 (L1a.1), 3495 (L1a.2), 3563 (L1a.3), 3564 (L1a.4), 3565 (L1a.5), 3566 (L1a.6), 3567 (L1a.7), 3568 (L1a.8), 3569 (L1a.9), 3570 (L1a.10), 3571 (L1a.11), 3582 (L1a.12), 1968 (L1a.13), 3011, 3012, 3013, 3418, 3422, 3562, D05, D07, D08, D10 and D11.

### Claim at position 10

-36. (canceled)

### Claim 37 (depends on 8)

The method of claim 8, wherein said LINGO-1 antagonist comprises a LINGO-1 antagonist polynucleotide.

### Claim at position 12

-71. (canceled)

### Claim 72 (depends on 8)

The method of claim 8, wherein said TrkB agonist is a TrkB agonist antibody or fragment thereof.

### Claim 73 (depends on 72)

The method of claim 72, wherein said TrkB agonist antibody or fragment thereof is selected from the group consisting of: 6E2, 7F5, 11E1, 16E11, 17D11, 19E12, 29D7 or a TrkB monoclonal antibody.

### Claim 74 (depends on 8)

The method of claim 8, wherein said TrkB agonist is a TrkB agonist polynucleotide.

### Claim at position 16

-78. (canceled)

### Claim 79 (depends on 8)

The method of claim 8, wherein said human subject has been diagnosed with a disease, disorder, or injury involving neurodegeneration.

### Claim at position 18

-107. (canceled)

### Claim 108

A method for treating glaucoma comprising administering to a human subject in need thereof a therapeutically effective amount of a LRR and Ig domain-containing Nogo receptor-interacting protein-1 (LINGO-1; SEQ ID NO:2) antagonist and a Neurotrophic tyrosine kinase receptor B (TrkB) agonist, wherein the TrkB agonist is a TrkB agonist antibody or antigen-binding fragment thereof.

### Claim 109 (depends on 108)

The method of claim 108, wherein the LINGO-1 antagonist comprises a soluble LINGO-1 polypeptide.

### Claim 110 (depends on 109)

The method of claim 109, wherein the soluble LINGO-1 polypeptide comprises
(i) a LINGO-1 LRR domain or a fragment, variant, or derivative thereof,
(ii) a LINGO-1 basic region C-terminal to the LRR domain or a fragment, variant, or derivative thereof,
(iii) a LINGO-1 immunoglobulin (Ig) domain or a fragment, variant, or derivative thereof, or
(iv) a combination of at least two of the LINGO-1 domains of (i) to (iii).

### Claim 111 (depends on 109)

The method of claim 109, wherein the soluble LINGO-1 polypeptide comprises amino acids 34-532 of SEQ ID NO: 2 or amino acids 36-532 of SEQ ID NO:2.

### Claim 112 (depends on 109)

The method of claim 109, wherein the soluble LINGO-1 polypeptide comprises amino acids 417-493 of SEQ ID NO:2.

### Claim 113 (depends on 109)

The method of claim 109, wherein the soluble LINGO-1 polypeptide further comprises a heterologous polypeptide fused to the soluble LINGO-1 polypeptide or a polymer.

### Claim 114 (depends on 113)

The method of claim 113, wherein the heterologous polypeptide is selected from the group consisting of an immunoglobulin fragment, serum albumin, a targeting protein, a reporter protein, and a purification-facilitating protein; or wherein the polymer is a polyalkylene glycol.

### Claim 115 (depends on 108)

The method of claim 108, wherein the LINGO-1 antagonist comprises a LINGO-1 antibody, or antigen-binding fragment thereof.

### Claim 116 (depends on 108)

The method of claim 108, wherein the LINGO-1 antagonist comprises a LINGO-1 antagonist polynucleotide selected from the group consisting of:
(i) an antisense polynucleotide;
(ii) a ribozyme;
(iii) a small interfering RNA (siRNA); and
(iv) a small-hairpin RNA (shRNA).

### Claim 117 (depends on 7)

The method of claim 7 wherein at least one of the LINGO-1 antagonist or TrkB agonist is administered directly into the eye.
